

Drug	ORR (%)	CRR (%)	PRR (%)	No. of patients	Phase	Setting	Reference
Dasatinib	26.7	0	20	15	II	R/R	Amrein et al., Clin Cancer Res 2011
Duvelisib	73.8	0.6	73.1	160	III	R/R	Flinn et al., Blood 2018
Fludarabine	71	23	48	52	III	TN	Johnson et al., Lancet 1996
Ibrutinib	86	4	82	269	III	TN	Burger et al., N Engl J Med 2015
Idelalisib	72	0	72	54	I	R/R	Brown et al., Blood 2014
ONO.4059	83	7	76	29	I	R/R	Danilov et al., Clin Cancer Res 2020
Ruxolitinib	0	0	0	13	II	R/R	Spaner et al., Haematologica 2016
Selinexor	33	0	33	6	I	R/R	Kuruvilla et al., Blood 2017
Sunitinib	0	0	0	18	II	R/R	Shanafelt et al., Leuk Lymphoma 2010
Venetoclax	80	33	47	258	III	R/R	Kater et al., Lancet Oncol 2024
Vismodegib	0	0	0	3	II	R/R	Houot et al., Ann Oncol 2016